Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Eli Lilly stock (LLY) popped by more than 5% on Wednesday after the Food and Drug Administration (FDA) approved the company's new weight-loss pill that Eli Lilly says can be taken "any time of day without food or water restrictions." The approval sets up a new phase of competition between Eli Lilly and its main competitor, Danish drugmaker Novo Nordisk (NVO), in the weight-loss drug space
The prevalence of NAFLD in the general population ranges from 10 to 24% [2,3,4,5]
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists has brought a significant shift in how healthcare professionals approach weight management and blood sugar control
The GLP-1s that can be prescribed for obesity include Novo's Wegovy injection and the drug's tablet form as well as Lilly's rival pill Foundayo and its obesity shot Zepbound in the KwikPen formulation
The staff are very knowledgeable and friendly
